135 completed. 135 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 135 | Completed 135 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC Efgartigimod PH20 SC - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 4 | Completed | argenx | 23 | 2024-12-10 | 2026-04-06 |
| A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China Dimethyl fumarate - Multiple Sclerosis | Phase 4 | Completed | Biogen | 60 | 2023-06-09 | 2025-05-16 |
| A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy Ocrelizumab - Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Completed | Hoffmann-La Roche | 70 | 2022-04-13 | 2026-04-15 |
| A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab Ocrelizumab - Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Completed | Hoffmann-La Roche | 26 | 2021-09-16 | 2026-01-14 |
| Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) BAF312, Baseline disease modifying therapies (DMTs), BNT162 - Secondary Progressive Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 41 | 2021-04-19 | 2024-06-20 |
| Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults Biological samples - Kidney Transplant, Myeloma | Phase 4 | Completed | Centre Hospitalier Régional d'Orléans | 196 | 2021-03-26 | 2025-12-23 |
| Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension) Mavenclad® - Multiple Sclerosis | Phase 4 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 219 | 2021-03-10 | 2025-01-22 |
| Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension) Mavenclad® - Multiple Sclerosis | Phase 4 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 280 | 2021-02-23 | 2024-05-28 |
| A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Quadrivalent influenza vaccine, Ofatumumab, iDMT - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 63 | 2021-01-14 | 2024-10-09 |
| Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation 11C-PBR28 - Multiple Sclerosis | Phase 4 | Completed | Massachusetts General Hospital | 22 | 2020-12-29 | 2025-12-30 |
| Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis Ocrelizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Johns Hopkins University | 10 | 2020-08-01 | 2025-02-17 |
| Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab Ocrelizumab - Multiple Sclerosis, Relapsing | Phase 4 | Completed | Genentech, Inc. | 179 | 2020-07-30 | 2026-02-04 |
| Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks TERIFLUNOMIDE - Multiple Sclerosis | Phase 4 | Completed | Sanofi | 82 | 2020-05-20 | 2025-09-24 |
| Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder Azathioprine - NMO Spectrum Disorder, Azathioprine Adverse Reaction | Phase 4 | Completed | First Affiliated Hospital of Guangxi Medical University | 63 | 2020-01-01 | 2023-06-09 |
| Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis Cladribine - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Gregory Wu | 47 | 2019-10-28 | 2026-07-28 |
| Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis Teriflunomide 14 MG - Multiple Sclerosis, Pharmacokinetics | Phase 4 | Completed | Jan Lycke | 12 | 2019-10-10 | 2022-12-12 |
| Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS) Data Collection - Multiple Sclerosis (MS) | Phase 4 | Completed | EMD Serono Research & Development Institute, Inc. | 662 | 2019-08-15 | 2023-10-31 |
| Short-term B-cell Depletion in Relapsing Multiple Sclerosis Ocrelizumab - Multiple Sclerosis | Phase 4 | Completed | Johns Hopkins University | 10 | 2019-04-01 | 2025-02-05 |
| Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada Blood draw for future biomarker analysis - Multiple Sclerosis | Phase 4 | Completed | Genzyme, a Sanofi Company | 13 | 2019-02-08 | 2022-03-28 |
| Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue Telephone-based Cognitive Behavioral Therapy, Modafinil - Multiple Sclerosis | Phase 4 | Completed | University of Michigan | 343 | 2018-11-15 | 2022-12-27 |
Showing 20 of 135. Sign in to see all of them.
Multiple Sclerosis (103) · Multiple Sclerosis, Relapsing-Remitting (45) · Fatigue (4) · Neuromyelitis Optica (3) · Recurrence (3) · Multiple Sclerosis, Chronic Progressive (2) · Muscle Spasticity (2) · Myelitis, Transverse (2) · Acquired Immunodeficiency Syndrome (1) · Anxiety Disorders (1) · Autoimmune Diseases of the Nervous System (1) · Breast Feeding (1) · COVID-19 (1) · Cerebellar Diseases (1) · Constipation (1)
Autoimmune Diseases (135) · Immune System Diseases (135) · Nervous System Diseases (135) · Autoimmune Diseases of the Nervous System (134) · Demyelinating Autoimmune Diseases, CNS (133) · Multiple Sclerosis (28) · Pathological Conditions, Signs and Symptoms (20) · Signs and Symptoms (14) · Neurologic Manifestations (7) · Disease Attributes (6) · Pathologic Processes (6) · Cranial Nerve Diseases (5) · Eye Diseases (5) · Infections (4)
Interferon beta-1a (23) · Fingolimod Hydrochloride (15) · Glatiramer Acetate (10) · Dimethyl Fumarate (9) · Natalizumab (9) · Interferon beta-1b (7) · Methylprednisolone (6) · ocrelizumab (6) · 4-Aminopyridine (5) · Alemtuzumab (4) · Cladribine (4) · teriflunomide (4) · Blood Specimen Collection (3) · Sugars (3) · Cetirizine (2)
Biogen (24) · Novartis Pharmaceuticals (17) · Merck KGaA, Darmstadt, Germany (7) · Bayer (4) · Brown, Theodore R., M.D., MPH (3) · EMD Serono (3) · Genzyme, a Sanofi Company (3) · Hoffmann-La Roche (3) · Sanofi (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · Teva Neuroscience, Inc. (3) · Germans Trias i Pujol Hospital (2) · Johns Hopkins University (2) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (2) · Multiple Sclerosis Center of Northeastern New York (2)
United States (54) · Germany (25) · France (23) · Italy (20) · Spain (20) · United Kingdom (16) · Belgium (15) · Canada (13) · Czechia (12) · Denmark (12) · Sweden (12) · Austria (11) · Poland (11) · Finland (10) · Netherlands (10)
MerriKay Oleen-Burkey, Ph.D. (3) · Theodore R Brown, MD, MPH (3) · Andrew D Goodman, MD (2) · Bianca Weinstock-Guttman, MD (2) · Cristina Ramo, MD (2) · Henrik B Jensen, MD (2) · Keith R Edwards, MD (2) · Adil Javed, MD (1)
PMID 12525714, PMID 40756532, PMID 40970353, PMID 41943490, PMID 10077661, PMID 10641699, PMID 10695888, PMID 10811692, PMID 12167681, PMID 14606742, PMID 15147583, PMID 16283615, PMID 16831964, PMID 16980142, PMID 17895294, PMID 17942508, PMID 18071030, PMID 18653737, PMID 18789766, PMID 18951800, PMID 19068404, PMID 19073949, PMID 19279320, PMID 19687024, PMID 1992392, PMID 20028712, PMID 2023770, PMID 20542736, PMID 20594850, PMID 20976768, PMID 21112438, PMID 21400196, PMID 21742556, PMID 22315143, PMID 22354743, PMID 2252363, PMID 2297305, PMID 23247892, PMID 23535489, PMID 23791482, PMID 23868508, PMID 23915113, PMID 23962697, PMID 24090757, PMID 24144876, PMID 24151639, PMID 24378281, PMID 24503204, PMID 24576156, PMID 24625687
2014 (3), 2015 (3), 2017 (3), 2016 (2), 2005 (1), 2018 (1), 2019 (1)